Evidence map›Paper›PMID 24486513›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2014

Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion.

JuFang Wang, Jianliang Song, Erhe Gao, Xue-Qian Zhang, Tongda Gu, Daohai Yu, Walter J Koch, Arthur M Feldman, Joseph Y Cheung

Abstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. FXYD proteins and sodium pump regulatory mechanisms.The Journal of general physiology · 2021
    Review
  3. Article
  4. Article
  5. Ca²⁺ entry via Trpm2 is essential for cardiac myocyte bioenergetics maintenance.American journal of physiology. Heart and circulatory physiology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

JuFang WangCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania;
Jianliang Song
Erhe Gao
Xue-Qian Zhang
Tongda Gu
Daohai Yu
Walter J Koch
Arthur M Feldman
Joseph Y Cheung
Temple University · US

Funding

Regulation of Beta-Adrenergic Receptor Signaling by S-NitrosylationP01HL075443 · NHLBI · DUKE UNIVERSITY · PI STAMLER, JONATHAN S. · 2004 to 2019
$26.1M
Targeted Cancer Therapeutics and Heart Failure: Mechanisms and Post-injury RepairP01HL091799 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI HOUSER, STEVEN R · 2008 to 2018
$23.1M
Targeting GRK2 in the HeartR01HL061690 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 1998 to 2022
$4.2M
EXERCISE TRAINING IN POSTINFARCT HEARTR01HL058672 · NHLBI · WEIS CENTER FOR RESEARCH-GEISINGER CLINC · PI CHEUNG, JOSEPH Y · 1998 to 2012
$3.6M
GRK and b-Arrestin Signaling in Cardiac RegenerationR01HL085503 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 2007 to 2015
$3.0M
Phospholemman and Cardiac ContractilityR01HL074854 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI CHEUNG, JOSEPH Y · 2005 to 2014
$2.8M
Gene Transfer and Myocardial FunctionR01HL056205 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 1998 to 2008
$2.6M
NHLBI NIH HHS P01-HL-75443NHLBI NIH HHS P01-HL-91799NHLBI NIH HHS R01 HL074854NHLBI NIH HHS R01-HL-56205NHLBI NIH HHS R01-HL-58672NHLBI NIH HHS R01-HL-61690NHLBI NIH HHS R01-HL-74854NHLBI NIH HHS R01-HL-85503
6 · The paper itself

Abstract

Phospholemman (PLM), when phosphorylated at Ser(68), inhibits cardiac Na+ / Ca2+ exchanger 1 (NCX1) and relieves its inhibition on Na+ -K+ -ATPase. We have engineered mice in which expression of the phosphomimetic PLM S68E mutant was induced when dietary doxycycline was removed at 5 wk. At 8-10 wk, compared with noninduced or wild-type hearts, S68E expression in induced hearts was ∼35-75% that of endogenous PLM, but protein levels of sarco(endo)plasmic reticulum Ca2+ -ATPase, α1- and α2-subunits of Na+ -K+ -ATPase, α1c-subunit of L-type Ca2+ channel, and phosphorylated ryanodine receptor were unchanged. The NCX1 protein level was increased by ∼47% but the NCX1 current was depressed by ∼34% in induced hearts. Isoproterenol had no effect on NCX1 currents but stimulated Na+ -K+ -ATPase currents equally in induced and noninduced myocytes. At baseline, systolic intracellular Ca2+ concentrations ([Ca2+]i), sarcoplasmic reticulum Ca2+ contents, and [Ca(2+)]i transient and contraction amplitudes were similar between induced and noninduced myocytes. Isoproterenol stimulation resulted in much higher systolic [Ca2+]i, sarcoplasmic reticulum Ca2+ content, and [Ca2+]i transient and contraction amplitudes in induced myocytes. Echocardiography and in vivo close-chest catheterization demonstrated similar baseline myocardial function, but isoproterenol induced a significantly higher +dP/dt in induced compared with noninduced hearts. In contrast to the 50% mortality observed in mice constitutively overexpressing the S68E mutant, induced mice had similar survival as wild-type and noninduced mice. After ischemia-reperfusion, despite similar areas at risk and left ventricular infarct sizes, induced mice had significantly higher +dP/dt and -dP/dt and lower perioperative mortality compared with noninduced mice. We propose that phosphorylated PLM may be a novel therapeutic target in ischemic heart disease.

Indexed as

MutationMyocardial ContractionVentricular Function, LeftAdrenergic beta-AgonistsAnimalsCalcium Channels, L-TypeCalcium SignalingCardiotonic AgentsDisease Models, AnimalMaleMembrane ProteinsMiceMice, TransgenicMyocardial InfarctionMyocardial Reperfusion InjuryPhosphoproteinsAdrenergic beta-AgonistsAtp1a1 protein, mouseAtp1a2 protein, mouseAtp2a2 protein, mouseCACNA1C protein, mouseCalcium Channels, L-TypeCardiotonic AgentsMembrane ProteinsNCX1 protein, mousephospholemmanPhosphoproteinsRyanodine Receptor Calcium Release ChannelSarcoplasmic Reticulum Calcium-Transporting ATPasesSodium-Calcium ExchangerSodium-Potassium-Exchanging ATPaseFXYD proteinsintracellular Ca2+ regulationin vivo hemodynamicsischemic cardiomyopathy

Identifiers

PMID24486513
PMCPMC3962630
OpenAlexW2003026378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.